Maria Zanardo Lloyd

Vice President, Dry Eye Portfolio at Harrow

Maria Zanardo Lloyd has extensive work experience in the pharmaceutical industry. Maria is currently working at Harrow as the National Sales Director, a role they have held since October 2023. Prior to this, they worked at Aerie Pharmaceuticals, where they held various positions including Senior Regional Sales Director and Regional Sales Director. Maria was responsible for strategic direction, team management, and driving the execution of promotional brands. Maria also served as the Mid-Atlantic District Sales Manager, where they built and trained a team focusing on launching a new medication for glaucoma. Before joining Aerie Pharmaceuticals, Maria worked at Allergan in roles such as Director of Key Accounts and Professional Relations, District Sales Manager, Field Training Manager, and Senior Sales Territory Manager. Maria'sresponsibilities included increasing sales, managing sales districts, training new hires, and promoting eye care products. Maria began their career at Janssen, where they worked as a Territory Sales Manager, promoting various medications in primary care and specialty settings.

Maria Zanardo Lloyd graduated from Radford University in 1998 with a Bachelor of Arts (B.A.) degree in Psychology.

Location

Norfolk, United States

Links


Org chart


Teams


Offices

This person is not in any offices


Harrow

2 followers

Harrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies that are accessible and affordable. Harrow owns U.S. commercial rights to ten FDA-approved ophthalmic pharmaceutical products. Harrow also owns and operates ImprimisRx, the leading U.S. ophthalmic‑focused pharmaceutical compounding business, which also serves as a mail-order pharmacy licensed to ship prescription medications in all 50 states. Harrow has non-controlling equity positions in Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc., companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in four late-stage drug candidates being developed by Surface and Melt.